Valeo Pharma Inc. (TSE:VPH – Get Free Report) was down 14.3% during trading on Wednesday . The stock traded as low as C$0.06 and last traded at C$0.09. Approximately 127,381 shares changed hands during mid-day trading, an increase of 133% from the average daily volume of 54,677 shares. The stock had previously closed at C$0.11.
Valeo Pharma Stock Down 19.0 %
The business’s fifty day moving average is C$0.17 and its two-hundred day moving average is C$0.19. The stock has a market cap of C$8.39 million, a price-to-earnings ratio of -0.22 and a beta of 2.56.
Valeo Pharma (TSE:VPH – Get Free Report) last posted its quarterly earnings results on Thursday, March 14th. The company reported C($0.08) EPS for the quarter, hitting the consensus estimate of C($0.08). The business had revenue of C$13.54 million during the quarter, compared to analyst estimates of C$15.30 million.
Valeo Pharma Company Profile
Valeo Pharma Inc, a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma.
See Also
- Five stocks we like better than Valeo Pharma
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- High-Yield Texas Instruments Could Hit New Highs Soon
- What Are Dividends? Buy the Best Dividend Stocks
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Technology Stocks Explained: Here’s What to Know About Tech
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Valeo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.